University Hospital	Southampton
	NHS Foundation Trust



NHS	USE	Specimen(s) received (Specimen(s) distribution
al & South	<u>ر</u>	

Date:

Specimen(s) received (local):

(central): BMT / Slides / BMA EDTA / PB EDTA / Cyto / other on: Histo MGG Flow Iron WGLS Sot.

WGLS Sot.

WGLS Sal. WGLS Sal.

Barcode

HaemOnc. Test Request Form

Referrer Information					atient Informa	ation		
Referring consultan	t			S	urname			
Hospital				F	irst Name			
Department				D	ate of Birth			Gender
Departmental Emai	l (secure)			Н	ospital numbe	er		
Telephone number				N	HS number			
□ NHS □ Pr	•				ddress			
	vace			,	dai ess			Postcode:
								i ostoode.
Diagnosis / clinical	details							
• How does the patie	nt meet							
the National Genon	nic Test							
Directory eligibility ^a	?							
 Clinical utility^b: 		Patient ma	anagement \square]			Infection I	Risk? Yes □ No □
Priority		Urgent □	Cancer path	nway 🗆	Routine□	Pleas	e notify the laborat	tory if clinically urgent
			·					
Sample details (see	reverse for	instructio	ns)	Operat			Tel./Bleep	
Lab reference number				Collect			Histo. macro.	UHS lab use only
(referrals to UHS)			-	date/ti			UHS LAB USE	
Specimen type		PB □ E	вма 🗆 вм	T ∐ C _\	togenetics \square	CSF	☐ FFPE ☐ Free	sh tissue \square Other \square
Refer to sample requirements over Please indicate if multiples of the so		(EDTA) (E	EDTA)				Biopsy 🗆 Res	ection 🗆
collected eg. BM √x2		☐ Trial (se	ent direct):				Biopsy Site:	
Haematology reque	est(s) ✓				ŀ	listopa	thology request(s)	✓
PB morphology □	BM morph	ology \square	Iron stain \square	BMT (l	naem) 🗌 🔠 I	BMT 🗆	☐ CD138 IHC ☐	☐ Congo Red ☐
Flow cytometry tes	t request(s)	✓ One EDTA	per sub-section					
Acute \square	Lympho	id \square	Evt	в 🗆 п	xt. T	Dlacn	na cell 🔲 🛮 Flow f	MRD □
Inc. blast enumeration			s required or know		-хі. і Ш	Fiasii		Away – specify BM / PB)
inc. blast chameration	Trogressive	b) i puncis u.	Trequired of know	m discuse			(Seliu A	Away - specify bivi / Fbj
Wessex Genomics I	aboratory S	Wessex Genomics Laboratory Service (Southampton) test request(s) ✓ One EDTA per sub-section						
JAK2 V617F (monit		ci vice (30	utnampton) t	est requ	est(s) √ One EDT	TA per sub	o-section	
-	oring\					ΓA per sub		
	<u> </u>		BRAF V600E		est(s) ✓ One EDT	ΓA per sub	MYD88 L265P	
Post allo transplant	<u> </u>					rA per sub		☐ hypermutation ☐
•	chimerism	5 🗆	BRAF V600E FVL/PTM ge	notyping		TA per sub	MYD88 L265P CLL IgHV somatic	
BCR::ABL1 qPCR -	chimerism	5 🗆	BRAF V600E	notyping		「A per sub	MYD88 L265P CLL IgHV somatic	hypermutation domain mutation**
BCR::ABL1 qPCR -	c himerism	5 🗆	BRAF V600E FVL/PTM ge BCR::ABL1 q	notyping PCR – M	onitoring ¹		MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase	domain mutation**
BCR::ABL1 qPCR - F	chimerism Presentation quencing**	5 🗆	BRAF V600E FVL/PTM ge BCR::ABL1 q	notyping PCR – M ia molecul	onitoring ¹ ar (genetics) MRI	D ² **	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality	T cell disease
BCR::ABL1 qPCR — F Whole Genome Sec Eligible tumour** p	resentation ¹ quencing** resentation		BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow u	notyping PCR – M ia molecul p (AML b	onitoring ¹	D ² **	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase	T cell disease
BCR::ABL1 qPCR – F Whole Genome Sec Eligible tumour** p Paired Germline (ap	resentation quencing** resentation prox. day 10	0-14)	BRAF V600E FVL/PTM ge BCR::ABL1 q	notyping PCR — M ia molecul p	onitoring ¹	D ² **	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is	T cell disease B cell disease used B cell disease
Whole Genome Sec Eligible tumour** p Paired Germline (ap LConfirm no circu	chimerism' Presentation quencing** resentation prox. day 10 lating tumo	0-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE	notyping PCR — M ia molecul p	onitoring ¹	D2 ** ury³)	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is	T cell disease
BCR::ABL1 qPCR – F Whole Genome Sec Eligible tumour** p Paired Germline (ap	chimerism' Presentation quencing** resentation prox. day 10 lating tumou	0-14)	BRAF V600E FVL/PTM ge BCR::ABL1 q Acute leukaem AML Follow u ALL Baseline ADULT AND TVA PATIE Date of diagnos	notyping PCR — M ia molecul p — (AML b — FOllowers only) sis/this tim	onitoring ¹	D2** ury³)	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is	T cell disease B cell disease used B cell disease
Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu	chimerism' Presentation quencing** resentation prox. day 10 lating tumou	0-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TVA PATIE Date of diagnos MRD Marker: Transcript/muta	notyping PCR — M ia molecul p — (AML b — Followits only* sis/this tim	onitoring ¹	D2** ury³)	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is	T cell disease B cell disease used B cell disease
Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu Must be confirmed before ge Please refer to central NHS England	chimerism' Presentation quencing** resentation prox. day 10 lating tumou	0-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TVA PATIE Date of diagnos MRD Marker: Transcript/muta	notyping PCR — M ia molecul p — (AML b — Followits only* sis/this tim	onitoring ¹	D2** ury³)	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is	T cell disease B cell disease used B cell disease
Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu Must be confirmed before ge Please refer to central NHS England	resentation quencing** resentation prox. day 10 lating tumou	0-14) ur cells cated.	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/muta	notyping PCR — M ia molecul p	onitoring ar (genetics) MRI aseline from WGLS Salisburbw up epoint:	D ² ** Liry ³) amples	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in	T cell disease B cell disease used B cell disease
Whole Genome Sec Eligible tumour** p Paired Germline (ap LyConfirm no circu Must be confirmed before ge Please refer to central NHS England details are entered.	c chimerism' Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens	0-14) ur cells exted.	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow u ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/muta Must be provided to er lisbury) test re	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	D ² ** ury ³) amples or sample	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in	T cell disease B cell disease used B cell disease
Whole Genome Sec Eligible tumour** p Paired Germline (ap L-Confirm no circu Must be confirmed before ge Please refer to central NHS England details are entered. Wessex Genomics I	resentation quencing** resentation prox. day 10 lating tumour tum	0-14) ur cells ected. ure clinical	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/muta Must be provided to en	notyping PCR — M ia molecul p	onitoring on itoring o	D ² ** ury ³) amples or sample ALL (T-	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in	T cell disease B cell disease mmunophenotyping report
BCR::ABL1 qPCR — F Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu Must be confirmed before ge Please refer to central NHS England details are entered. Wessex Genomics Myeloid disorders (N G-banding	c chimerism Presentation quencing** resentation prox. day 10 lating tumou rumline sample is colle eligibility criteria. Ens aboratory \$ MDS, MPN, Al FISH	0-14) ur cells ceted. ure clinical Cervice (Samul, SM, CM) My	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut: Must be provided to er lisbury) test re IL***) eloid NGS pane	notyping PCR — M ia molecul p	onitoring ¹ onitoring ¹ onitoring ¹ onitoring ¹ onitoring ¹ onitoring ¹ onitoring of season on the season of season on the season of the season on the season of the season on the season of the season on the season of the season on the season on the season on the season of the season of the season of the season of the season on the season of the	D ² ** ury³) camples or sample ALL (T- G-band	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease B cell disease mmunophenotyping report SNP array
Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu Must be confirmed before ge Please refer to central NHS England details are entered. Wessex Genomics I Myeloid disorders (NG-banding Denoming MPN panel (JAK2 V61)	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens Aboratory S MDS, MPN, A FISH 7F/CALR/MP	0-14) O-14) O-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut. Must be provided to en lisbury) test re LE***) reloid NGS pane	notyping PCR — M ia molecul p	onitoring on itoring o	D ² ** amples or sample ALL (T- G-band Lympho	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease T cell disease B cell disease mmunophenotyping report SNP array L, etc.)
Whole Genome Sec Eligible tumour** p Paired Germline (ap L. Confirm no circu Must be confirmed before ge Please refer to central NHS England details are entered. Wessex Genomics I Myeloid disorders (NG-banding MPN panel (JAK2 V61 KIT D816V (ddPCR)	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens Aboratory S MDS, MPN, Al FISH 7F/CALR/MP.	0-14) O-14) O-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut: Must be provided to er lisbury) test re IL***) eloid NGS pane	notyping PCR — M ia molecul p	onitoring on itoring on itoring on itoring on itoring on itoring on itorical salish on it	D ² ** amples or sample ALL (T- G-band Lymphe FISH	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease B cell disease mmunophenotyping report SNP array
Whole Genome Sec Eligible tumour** p Paired Germline (ap Lagrange Germline) Lagrange Germline (ap Lagrange Germline) Lagrange Germline (ap Lagrange Germline) Must be confirmed before germlease refer to central NHS England details are entered. Wessex Genomics I Myeloid disorders (N G-banding MPN panel (JAK2 V61 KIT D816V (ddPCR) FIP1L1-PDGFRA (diag	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens Aboratory \$ IDS, MPN, Al FISH 7F/CALR/MP Ext. K nosis)	0-14) O-14) O-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut. Must be provided to en lisbury) test re LE***) reloid NGS pane	notyping PCR — M ia molecul p	onitoring on itoring on itoring on itoring on itoring on itoring on itorical salish on it	D ² ** amples or sample ALL (T- G-band Lymphe FISH	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease T cell disease B cell disease mmunophenotyping report SNP array L, etc.)
Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu Must be confirmed before ge Please refer to central NHS England details are entered. Wessex Genomics Myeloid disorders (NG-banding Debanding	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens MDS, MPN, Al FISH 7F/CALR/MP. Ext. K mosis) ar testing)	O-14) O-14)	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut: Must be provided to er lisbury) test re [Isbury] test re [IL***] reloid NGS panel [12) rel (if D816V neg	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	or sample ALL (T- G-band Lympho FISH Lympho Myelor	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling FISH oid (Mature: CLL, NHI	T cell disease B cell disease mmunophenotyping report SNP array L, etc.) S seq.
Whole Genome Sec Eligible tumour** p Paired Germline (ap	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens MDS, MPN, Al FISH FISH FISH Ext. K nosis) Ar testing	O-14) Our cells Our cells	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut: Must be provided to en isbury) test re isbury) test re itsbury) test re	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	or sample ALL (T- G-band Lympho FISH Lympho Myelor	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease B cell disease mmunophenotyping report SNP array L, etc.) S seq.
Whole Genome Sec Eligible tumour** p Paired Germline (ap Confirm no circu Must be confirmed before ge Please refer to central NHS England details are entered. Wessex Genomics Myeloid disorders (NG-banding Debanding	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens MDS, MPN, Al FISH FISH FISH Ext. K nosis) Ar testing	O-14) Our cells Our cells	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut: Must be provided to en isbury) test re isbury) test re itsbury) test re	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	or sample ALL (T- G-band Lympho Lympho CMyelor CD138-	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling FISH oid (Mature: CLL, NHI	T cell disease B cell disease mmunophenotyping report SNP array L, etc.) S seq.
Whole Genome Sec Eligible tumour** p Paired Germline (ap LyConfirm no circu Must be confirmed before gerelease refer to central NHS England details are entered. Wessex Genomics I Myeloid disorders (Nathon Company	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens MDS, MPN, Al FISH FISH FISH Ext. K nosis) Ar testing	O-14) Our cells Our cells	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/mut: Must be provided to en isbury) test re isbury) test re itsbury) test re	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	or sample ALL (T- G-band Lympho Lympho CMyelor CD138-	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease B cell disease mmunophenotyping report SNP array L, etc.) S seq. nnly (storage)
Whole Genome Sec Eligible tumour** p Paired Germline (ap Lagrange Germline) Must be confirmed before gerease refer to central NHS England details are entered. Wessex Genomics I Myeloid disorders (NG-banding MPN panel (JAK2 V61 KIT D816V (ddPCR) FIP1L1-PDGFRA (diag AML (urgent molecul FLT3-ITD FLT3-ITD FLT3-ITD Requester	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens MDS, MPN, Al FISH FISH FISH Ext. K nosis) Ar testing	O-14) Our cells Our cells	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/muta Must be provided to en Ilisbury) test re 12) el (if D816V neg	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	or sample ALL (T- G-band Lympho Lympho CMyelor CD138-	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease B cell disease mmunophenotyping report SNP array L, etc.) S seq. nly (storage) nly (storage)
Whole Genome Sec Eligible tumour** p Paired Germline (ap LyConfirm no circu Must be confirmed before gerelease refer to central NHS England details are entered. Wessex Genomics I Myeloid disorders (N G-banding	chimerism Presentation quencing** resentation prox. day 10 lating tumou rmline sample is colle eligibility criteria. Ens MDS, MPN, Al FISH FISH FISH Ext. K nosis) Ar testing	O-14) Our cells Our cells	BRAF V600E FVL/PTM get BCR::ABL1 q Acute leukaem AML Follow ut ALL Baseline ADULT AND TYA PATIE Date of diagnos MRD Marker: Transcript/muta Must be provided to en Ilisbury) test re 12) el (if D816V neg	notyping PCR — M ia molecul p	onitoring onitoring onitoring onitoring onitoring onitoring on the control on the	or sample ALL (T- G-band Lympho Lympho CMyelor CD138-	MYD88 L265P CLL IgHV somatic BCR::ABL1 kinase Clonality A progressive testing strategy is Include histology / in details) and B-) ling	T cell disease B cell disease mmunophenotyping report SNP array L, etc.) S seq. nnly (storage)

Sample transport

The referring laboratory is responsible for the safe transfer of tissue and it is thus recommended that Royal Mail Recorded Delivery or an equivalent tracked postal service is used.

Transport tracking ID

Please send flow samples to:	WGLS (Southampton) samples to:	WGLS (Salisbury) samples to:	BMT samples to:
Department of Immunology Laboratory Medicine University Hospital Southampton NHFT, Tremona Road, Southampton, Hampshire, SO16 6YD.	Formerly Department of Molecular Pathology Duthie Link Building, Mailpoint 225, University Hospital Southampton NHSFT, Tremona Road, Southampton, Hampshire, SO16 6YD.	Formerly Wessex Regional Genetics Laboratory Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ	Department of Cellular Pathology, Pathology Block, Level E, Mailpoint 002. University Hospital Southampton NHSFT, Tremona Road, Southampton, Hampshire, SO16 6YD.
UKAS ref: 8696 20381 206615 / 02381 206640	UKAS ref: 9194 ☎ 02381 206638	UKAS ref: 1175 ☎ 01722 429080	UKAS Ref: 8178 ☎ 023 8120 4879
☐ immunologylab@uhs.nhs.uk	■ U2381 200038 ■ wgls_cancergenomics@uhs.nhs.uk ■ wgs_cancerwgls@uhs.nhs.uk (wgs only)	shc-tr.WRGLdutyscientist@nhs.net	■ 023 8120 4679 ■ cellpath@uhs.nhs.uk
www.uhs.nhs.uk/health-professionals/pathology- services/handbook/laboratorymedicine	www.uhs.nhs.uk/health-professionals/pathology-serv	www.uhs.nhs.uk/health-professionals/pathology- services/handbook/cellularpathology	

Sample requirements

Details on both the referral card and the sample tube should be complete and legible. A minimum of 3 ID points are required. We reserve the right to refuse to process samples with incomplete, illegible or ambiguous patient information. Any samples in the wrong tube or medium, or which are subject to significant delay in transit, are liable to be rejected.

- a. FOR ALL GENOMIC TESTING, PLEASE ALSO PROVIDE SPECIFIC INFORMATION DETAILING HOW THE PATIENT MEETS THE NATIONAL GENOMIC TEST DIRECTORY (NGTD) ELIGIBILITY CRITERIA FOR THE TEST BEING REQUESTED (see http://www.england.nhs.uk/publication/national-genomic-test-directories for further information)
- b. FOR ALL GENOMIC TESTING, PLEASE INDICATE HOW TESTING WILL IMPACT PATIENT CARE. PATIENT MANAGEMENT INCLUDES DETERMINING THERAPEUTIC DECISIONS AND/OR CLINICAL INVESTIGATION AND/OR SURVEILLANCE PROGRAMMES.

Flow cytometry

WGLS (Southampton)
Formerly Molecular Pathology

EDTA whole blood, bone marrow or fluid in universal container.

Sample must arrive and be tested within 72 hours of collection

FFPE: Send FFPE block (preferred) or tissue scrolls (3 x 20μm). Scrolls should be prepared on a clean microtome, ideally using a fresh blade per case, to avoid the risk of cross-contamination.

PB: Send minimum 3.4ml EDTA as an independent sample. This must **not** have been used previously on an automated laboratory analyser. ¹For BCR-ABL analysis, if PB sample, please send minimum 12ml EDTA. TKI information and dates must be provided in clinical details to enable effective monitoring.

- ² For MRD analysis, if PB, please send 20ml EDTA, if BM, please send 5ml EDTA. Patients monitored at unusual laboratories must be highlighted and the MRD lab identified.
- ³ AML cases where the diagnostic sample identifies an MRD marker as part of the usual genetic work up, will have material sent from the WGLS Salisbury sample (the standard cytogenetics sample <u>no additional sample required specifically for AML baseline MRD</u>) to WGLS Southampton for RNA extraction and onward sending to the relevant laboratory.
- ⁴Adult patients (>26years of age), TYA patients (16-25years of age) only. Paediatric patients remain under the care of the CNS/trials team(s). Samples for RNA extraction must arrive in this laboratory within 48 hours of collection.
- ⁵ This laboratory performs whole PB/BM chimerism. This is not requesting Lineage Specific Chimerism, which is sent directly from clinical teams. ** This is a send away test.

BM:

- Conventional cytogenetics for acute leukaemias, MDS, MPD and AA: 0.5- 1ml in transport medium (but lithium heparin accepted)
- For new paediatric acute leukaemias also send KCH (3 drops of BM in KCH to be fixed at referring laboratory); if transport medium is not available, send in lithium heparin.
- Molecular studies of FLT3-ITD, FLT3-TKD, NPM1, IDH1, IDH2, TP53, KIT, JAK2, JAK2 exon 12, CALR, MPL and Myeloid NGS panel: 2-3ml in EDTA; however, material sent in BM transport medium or lithium heparin is acceptable.

PB:

- Conventional cytogenetics for new diagnosis CML, myelofibrosis or new acute leukaemias if no BM available: 5ml in lithium heparin.
- FISH for CLL/MCL and TP53 mutation testing: 5ml in lithium heparin.

quality control procedures including validation of new genetic tests.

- Molecular studies of JAK2, CALR, MPL, myeloid NGS panel, etc.: 5ml in EDTA.
- FIP1L1-PDGFRA: 10ml in EDTA.

Smears: for CLL or NHL with suitable FISH markers, FISH can be attempted on freshly made, unfixed, unstained smears (at least 4 smears) if no fresh material is available. Please note that FISH can be attempted on smears that have been stored for some time if no other material available. Biopsies: FFPE sections / tumour dabs: slides containing unstained FFPE sections (3-4µm) or tumour dabs should contain at least 2 patient identifiers. Please package in a slide box. For large FFPE sections, please also send H&E slide with the tumour area appropriately marked.

Other Tissues: lymph node, spleen, skin etc. should be sent in transport medium upon previous discussion with the laboratory.

Please phone as soon as possible if anything is sent by courier which might arrive outside normal working hours. There is an on-call rota for acute presentations and Burkitt lymphoma after hours on a Friday or at the weekend (please phone the switch board on 01722 336262).

In submitting samples the clinician confirms that consent has been obtained for testing and storage. Anonymised stored samples may be used for

ular ology Specimen to be submitted in 60ml pot containing 10% neutral buffered formalin (ratio of 10:1). Direct purchase from Genta Medical.